[Prevalence of hand dysfunction in cerebral palsy following Botulinum toxin therapy].
OBJECTIVE
To examine the level of dependence, the functional class, the most frequent type of compromise and the proprioception of the hand in spastic cerebral palsy following the application of botulinum toxin, as well as to determine the sociodemographic characteristics of the individuals involved.


METHODS
We conducted a cross-sectional study of 21 spastic patients with extrinsic muscle involvement, of both sexes and a mean age of 15.4 +/- 5.6 years, who attended the neuro-rehabilitation outpatients department and were treated with botulinum toxin in the muscles responsible for the functional movements in the hand; they were evaluated after a mean period of 2.1 years. Patients were subjected to procedures such as a semi-structured interview, the FIM (Functional Independence Measurement) scale, Hausen's functional characterisation, Zancolli classification and a proprioception test.


RESULTS
There was a predominance of females (57% of patients) and of a basic level of schooling. On the FIM scale, 38% of the patients presented modified independence, without help; 23.8% belonged to Hausen grade 3 (grasping and holding an object steady with the help of the other hand). On the Zancolli classification, 54% belonged to type III (the fingers can only be extended if the fist is bent more than 70 masculine); perception of movement is absent (76.2%) and the sense of position of the movement is altered (54.2%).


CONCLUSIONS
Findings confirmed the existence of a high rate of modified independence, grade 3 (Hausen), together with type III involvement (Zancolli) and alterations affecting proprioception. Data from the study show the importance of occupational therapy as part of the care received by patients with cerebral palsy following the administration of botulinum toxin type A.
Alahmar-Bianchin
M
M
Facultad de Medicina, São Jose do Rio Preto, São Paulo, Brasil.
Saraiva-Storti
H C
HC
Fornari-Chueri
R
R
Lucato
R V
RV
D000293:Adolescent; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy / Q000503:physiopathology; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D006225:Hand / Q000503:physiopathology*; D006801:Humans; D008297:Male; D009068:Movement / Q000502:physiology; D009128:Muscle Spasticity / Q000188:drug therapy; D009460:Neurologic Examination; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D026741:Physical Therapy Modalities
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A